Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Shares Outstanding (2016 - 2025)

Haemonetics (HAE) has 15 years of Shares Outstanding data on record, last reported at $46.8 million in Q4 2025.

  • For Q4 2025, Shares Outstanding fell 6.78% year-over-year to $46.8 million; the TTM value through Dec 2025 reached $46.8 million, down 6.78%, while the annual FY2025 figure was $48.2 million, 5.06% down from the prior year.
  • Shares Outstanding reached $46.8 million in Q4 2025 per HAE's latest filing, roughly flat from $46.7 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $51.3 million in Q3 2022 and bottomed at $46.7 million in Q3 2025.
  • Average Shares Outstanding over 5 years is $50.1 million, with a median of $50.7 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding: rose 1.08% in 2021, then decreased 7.21% in 2025.
  • A 5-year view of Shares Outstanding shows it stood at $51.1 million in 2021, then fell by 1.21% to $50.4 million in 2022, then increased by 0.68% to $50.8 million in 2023, then decreased by 1.08% to $50.2 million in 2024, then decreased by 6.78% to $46.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding were $46.8 million in Q4 2025, $46.7 million in Q3 2025, and $48.2 million in Q2 2025.